CODX experienced severe financial deterioration with revenue collapsing 84% and a massive 90% reduction in outstanding shares from 33.6M to 3.6M, indicating either a significant reverse stock split or major corporate restructuring.
The dramatic reduction in share count combined with plummeting revenue and assets suggests either a major reverse stock split to maintain listing requirements or a fundamental business restructuring. The company's pivot from COVID-19 testing to a multiplex respiratory test following FDA submission withdrawal indicates strategic challenges in their core regulatory pathway.
CODX shows severe financial distress with revenue collapsing from $3.9M to $622K and gross profit falling 86% to just $400K, while the company executed $1.4M in share buybacks despite deteriorating operations. Total assets declined 61% to $24.7M and stockholders' equity dropped 62% to $20.6M, though cash increased significantly to $11.9M, possibly from asset liquidation or financing activities. The overall picture signals a company in significant financial decline requiring urgent strategic repositioning.
Cash position surged 304.7% — strong cash generation or capital raise providing significant financial cushion.
Buyback activity reduced 90.4% — capital being redeployed elsewhere or cash conservation underway.
Deposits declined 88.5% — significant outflows warrant immediate investigation into funding stability.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Revenue declined 84.1% — significant demand weakness or market share loss warrants investigation.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 61.3% — asset sales, write-downs, or balance sheet optimization underway.
Current assets declined 57.6% — monitor working capital adequacy and short-term liquidity.
Liabilities reduced 57.5% — deleveraging improves balance sheet strength and financial flexibility.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →